Find trending articles through Social News Discovery®! Providing a collaboration of news through social media technologies.
Follow your friends and create your own Online Social Newspaper! Invite your friends to follow you from Facebook. Filter the news articles you see by section, clipper, or mood. Rate each article and comment on all news clips!
Receive site and email notifications about comments and news clips that you are collaborating on!
Get the latest news on the Everyone page, the viral and trending news clips will always be at the top! See the trending news and articles!
"Florence, Italy - 21 May 2016: European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure are published today in European Heart Journal1 and the European Journal of Heart Failure, and presented at", www.sciencecodex.com
"European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure are published today in European Heart Journal and the European Journal of Heart Failure, and presented at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure.", www.eurekalert.org
"LONDON: New global guidelines on the treatment of heart failure strongly endorse the use of Novartis' Entresto, boosting the prospects for a drug that has struggled to gain traction since its launch last year. US and European heart experts gave the highest `class 1` recommendation to Entresto for use in patients with heart failure, a debilitating condition in which the heart is unable to pump enough blood around the body.The guidance in the key US market says that Entresto should replace two", www.brecorder.com
"Novartis (NVS) announced that Entresto (sacubitril/valsartan) has been given a Class I recommendation in updated clinical practice guidelines simultaneously released by the American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Failure Society of America (HFSA) in the US, and the European Society of Cardiology in the EU.", www.rttnews.com
"Novartis has announced the launch of FortiHFy, a large global clinical trial program comprising more than 40 active or planned studies of combination sacubitril and valsartan for the treatment of HF. The goal of the Fortify Heart Failure clinical evidence and patient quality of life (FortiHFy) program is to generate additional data on symptom reduction, efficacy, safety, quality of life and", www.healio.com
"ZURICH: Novartis's heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction. Novartis, which on Thursday described the trials as `the largest global clinical programme` for heart failure, is seeking among other things to assuage doctors' concerns over switching patients to Entresto when they are stable on older medicines. Such worries, on top of insurers' reluctance to pay, have cont", www.brecorder.com
"The Novartis heart failure med Entresto hasn't hit the ground running as expected, partly because U.S. payers have set up hurdles for coverage. Now, the Swiss drugmaker is putting more money into investigating Entresto’s ability to deliver the kind of payoffs that insurers want--and help the drug expand its target market.", www.fiercepharma.com